CTEP (RO4956371)

Catalog No.S2861

CTEP is a novel, long-acting, orally bioavailable allosteric antagonist of mGlu5 receptor with IC50 of 2.2 nM, shows >1000-fold selectivity over other mGlu receptors.

Price Stock Quantity  
In DMSO USD 420 In stock
USD 270 In stock
USD 370 In stock
USD 1070 In stock
USD 2470 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

CTEP (RO4956371) Chemical Structure

CTEP (RO4956371) Chemical Structure
Molecular Weight: 391.77

Validation & Quality Control

Quality Control & MSDS

Related Compound Libraries

CTEP (RO4956371) is available in the following compound libraries:

Product Information

  • Compare GluR Chemicals
    Compare GluR Chemicals
  • Research Area

Product Description

Biological Activity

Description CTEP is a novel, long-acting, orally bioavailable allosteric antagonist of mGlu5 receptor with IC50 of 2.2 nM, shows >1000-fold selectivity over other mGlu receptors.
Targets mGlu5
IC50 2.2 nM [1]
In vitro CTEP inhibits quisqualate-induced Ca2+ mobilization with an IC50 of 11.4 nM and [3H]IP accumulation with an IC50 of 6.4 nM in HEK293 cells stably expressing human mGlu5. CTEP inhibits the constitutive activity of human mGlu5 by approximately 50% with an IC50 of 40.1 nM in HEK293 cells stably expressing human mGlu5. [1]
In vivo CTEP is significantly active at doses of 0.1 mg/kg and 0.3 mg/kg in treatment of anxiety in mouse. CTEP significantly increases drinking time at doses of 0.3 mg/kg and 1.0 mg/kg in the Vogel conflict drinking test in rat, whereas it has no effect at lower doses. The half-life of CTEP (oral) is 18 h, and the B/P ratio based on total drug concentrations in plasma and whole brain homogenates is 2.6 in mice. After single oral doses of 4.5 and 8.7 mg/kg CTEP formulated as microsuspension in a saline/Tween vehicle administrated to adult C57BL/6 mice is rapidly absorbed and achieves close to maximal exposure after approximately 30 min. Chronic administration in adult mice with a dose of 2 mg/kg p.o. every 48 h for 2 months reaches a minimal CTEP brain exposure of 240 ng/g. CTEP fully displaces [3H]ABP688 in mouse brain regions known to express mGlu5, and 50% displacement is achieved with doses producing an average compound concentration of 77.5 ng/g measured in whole brain homogenate. [1] CTEP (2 mg/kg p.o. bid) achieves uninterrupted mGlu5 occupancy per 48 hours in mice. CTEP (2 mg/kg p.o.) treatment corrects elevated hippocampal long-term depression, excessive protein synthesis, and audiogenic seizures in the Fmr1 knockout mouse. [2]
Features

Protocol(Only for Reference)

Kinase Assay: [1]

Radioligand Binding Assays For all filtration radioligand binding assays, membrane preparations expressing the target receptors or receptor combinations are resuspended in radioligand binding buffer (15 mM Tris-HCl, 120 mM NaCl, 5 mM KCl, 1.25 mM CaCl2, and 1.25 mM MgCl2, pH 7.4), and the membrane suspension is mixed with the appropriate concentrations of radioligand and nonlabeled drugs in 96-well plates in a total volume of 200 μL and incubated for 60 min at the appropriate temperature. At the end of the incubation, membranes are filtered onto Whatman Unifilter preincubated with 0.1% polyethyleneimine in wash buffer (50 mM Tris-HCl, pH 7.4) with a Filtermate 196 harvester and washed three times with ice-cold wash buffer. Radioactivity captured on the filter is quantified on a Topcount microplate scintillation counter with quenching correction after the addition of 45 μL of MicroScint 40 per well and shaking for 20 min. The concentration of membranes and incubation time is determined for each assay in pilot experiments.

Animal Study: [1]

Animal Models Male Sprague-Dawley rats
Dosages 1.0 mg/kg
Administration orally
Solubility 30% propylene glycol, 5% Tween 80, 65% D5W, 6 mg/mL
1

References

Clinical Trial Information( data from http://clinicaltrials.gov)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT01322802 Recruiting Stage III Ovarian Epithelial Cancer|Stage III Ovarian Germ Cell Tumor|Stage IV Ovarian Epithelial Cancer|Stage IV Ovarian Germ Cell Tumor FredHutchinsonCancerResearchCenter|Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium|NationalCancerInstitute(NCI) 2012-03 Phase 1
NCT01536067 Recruiting Waldenstr枚m Macroglobulinemia RoswellParkCancerInstitute|NationalCancerInstitute(NCI) 2012-04 Phase 2
NCT01606241 Recruiting Recurrent Breast Cancer|Recurrent Fallopian Tube Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Ovarian Germ Cell Tumor|Recurrent Primary Peritoneal Cavity Cancer etc. MayoClinic 2012-07 Phase 1
NCT01632332 Recruiting HER2-positive Breast Cancer|Male Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer MayoClinic|TapImmune,Inc. 2012-07 Phase 1
NCT01729884 Recruiting HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer FredHutchinsonCancerResearchCenter|Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium|NationalCancerInstitute(NCI) 2012-12 Phase 2

Chemical Information

Download CTEP (RO4956371) SDF
Molecular Weight (MW) 391.77
Formula

C19H13ClF3N3O

CAS No. 871362-31-1
Storage 3 years -20℃Powder
6 months-80℃in DMSO
Syonnyms
Solubility (25°C) * In vitro DMSO 78 mg/mL (199 mM)
Water <1 mg/mL (<1 mM)
Ethanol 10 mg/mL (25 mM)
In vivo 30% propylene glycol, 5% Tween 80, 65% D5W, 6 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name Pyridine, 2-chloro-4-[2-[2,5-dimethyl-1-[4-(trifluoromethoxy)phenyl]-1H-imidazol-4-yl]ethynyl]-

Preparing Stock Solutions

Stock Solution (1ml DMSO) 1mM 10mM 20mM 30mM
Mass(mg) 0.39177 3.9177 7.8354 11.7531

Research Area

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related GluR Chemicals

  • NMDA (N-Methyl-D-aspartic acid)

    NMDA(N-Methyl-D-aspartic acid)is a specific agonist for NMDA receptor mimicking the action of glutamate, the neurotransmitter which normally acts at that receptor. Phase 4.

  • VU 0364439

    VU 0364439 is a mGlu4 positive allosteric modulator (PAM), with EC50 of 19.8 nM.

    Features:The most potent mGlu4 PAM reported to date.

  • Vortioxetine (Lu AA21004) HBr

    Vortioxetine (Lu AA21004) is a multimodal serotonergic agent, inhibits 5-HT1A, 5-HT1B, 5-HT3A, 5-HT7 receptor and SERT with IC50 of 15 nM, 33 nM, 3.7 nM, 19 nM and 1.6 nM, respectively. Phase 3.

    Features:A multimodal antidepressant.

  • LY404039

    LY404039 is a potent agonist of recombinant human mGlu2/mGlu3 receptors with Ki of 149 nM/92 nM, shows >100-fold selectivity over ionotropic glutamate receptors, glutamate transporters, and other receptors. Phase 3.

    Features:Under investigation as an exciting new medicine that may herald the arrival of third-generation antipsychotic drugs.

  • Latrepirdine

    Latrepirdine is an antihistamine drug.

  • MK-801 (Dizocilpine)

    Dizocilpine is a potent N-methyl-D-aspartate (NMDA) receptor antagonist with Ki of 30.5 nM.

  • (-)-Huperzine A (HupA)

    (-)-Huperzine A is a potent, highly specific and reversible inhibitor of acetylcholinesterase (AChE) with Ki of 7 nM, exhibiting 200-fold more selectivity for G4 AChE over G1 AChE. Phase 4.

    Features:Greater penetration of the blood-brain barrier, higher oral bioavailability, and longer AChE inhibition relative to tacrine, donepezil, and rivastigmine.

  • (-)-MK 801 Maleate

    MK-801 is a potent, selective and non-competitive NMDA receptor antagonist with Kd of 37.2 nM in rat brain membranes.

  • CTEP (RO4956371)

    CTEP is a novel, long-acting, orally bioavailable allosteric antagonist of mGlu5 receptor with IC50 of 2.2 nM, shows >1000-fold selectivity over other mGlu receptors.

  • ADX-47273

    ADX47273 is a potent and specific mGlu5 positive allosteric modulator(PAM) with EC50 of 0.17 μM, showing no activity at other mGlu subtypes.

Recently Viewed Items

Tags: buy CTEP (RO4956371) | CTEP (RO4956371) supplier | purchase CTEP (RO4956371) | CTEP (RO4956371) cost | CTEP (RO4956371) manufacturer | order CTEP (RO4956371) | CTEP (RO4956371) distributor
Contact Us